Anlon Healthcare IPO

About Anlon Healthcare IPO

The IPO of Anlon Healthcare Ltd is a 100% book-built offer. It consists entirely of a fresh issue of up to 1,33,00,000 equity shares. There’s no offer for sale in this IPO. The price band is ₹86 to ₹91 per share and the lot size is 164 shares.

The IPO opens on August 26, 2025 and closes on August 29, 2025. The listing date is on or before September 3, 2025 and the allotment date is on or before September 1, 2025. The credit of shares to the Demat account will take place on September 2, 2025, while the initiation of refund will take place on September 2, 2025.

Anlon Healthcare Ltd is a chemical manufacturing company engaged in manufacturing of; (i) high purity advance pharmaceutical intermediates (Pharma Intermediate) which serves as raw material/ key starting material in the manufacturing of active pharmaceutical ingredients; and (ii) active pharmaceutical ingredients (APIs) which serves as a raw material for pharmaceutical formulations in preparation of various type of Finished Dosage Formula (FDF) such as tablet, capsules, ointment, syrup etc, ingredients in nutraceuticals formulations, personal care products and animal health products.

Objectives of Anlon Healthcare IPO

The company plans to utilise the proceeds received from the IPO for:

• Funding capital expenditure requirements for expansion of its manufacturing facility
• Full or part repayment and/or prepayment of certain outstanding secured borrowings availed by it
• Funding the working capital requirements
• Unidentified inorganic acquisitions and general corporate purposes

Industry Outlook

The Indian pharmaceutical industry is ranked as the third largest in the world, in terms of volumes of drugs manufactured and thirteenth largest, in terms of value. The country is also the world’s largest supplier of cost-effective generic drugs, and accounts for nearly one fifth of the global trade in generic drugs. India has achieved an enviable position in the global generic drug market on the back of its strength in organic chemical synthesis and process engineering.

India’s pharmaceutical industry has displayed a consistent upward trajectory over the past few years, growing from INR 3,281 billion in FY 2021 to an estimated INR 4741 billion in FY 2025. Between FY 2021 – FY 2025, annual turnover in the Indian Pharmaceutical Industry increased at a CAGR of 10%.

The industry has evolved from being largely generic-focused to increasingly embracing high-value segments such as biosimilars, biologics, and complex generics. India’s positioning as the “pharmacy of the world” has gained further credibility post-COVID, with global recognition of its role in supplying affordable, high-quality medicines to over 200 countries.

Company Information

Anlon HealthCare Ltd is a chemical manufacturing company engaged in manufacturing of; (i) high purity advance pharmaceutical intermediates (“Pharma Intermediate”) which serves as raw material/ key starting material in the manufacturing of active pharmaceutical ingredients; and (ii) active pharmaceutical ingredients (“APIs”) which serves as a raw material for pharmaceutical formulations in preparation of various type of Finished Dosage Formula (“FDF”) such as tablet, capsules, ointment, syrup etc, ingredients in nutraceuticals formulations, personal care products and animal health products.

Its products span across the family of pharmaceutical intermediates, active pharmaceutical ingredients, nutraceutical APIs and ingredients for personal care and veterinary API. Its active pharmaceutical ingredient products are manufactured in accordance with Indian and international pharmacopeia standards such as IP, BP, EP, JP, USP.

Strengths of Anlon Healthcare IPO

• Strong product portfolio and scalable business
• Strong promoters and experienced management team
• High entry and exit barriers due to long customer approval cycles and strict product standards
• In-house testing, quality control and quality assurance for quality control
• Focus on quality, environment, health and safety

Risks of Anlon Healthcare IPO

• Subject to strict quality requirements and regular customer audits, non-compliance of which could lead to order cancellation
• Failure to maintain product quality may lead to customer dissatisfaction
• Limited operating history in manufacturing
• Delay in placing orders for equipment, plant and machinery could lead to disruption
• Products exposed to risk of contamination and adulteration

Anchor Investor Bidding Date

The anchor investor bidding date is on August 25, 2025.

IPO Registrar and Book Running Lead Manager

KFin Technologies Ltd is the registrar of this IPO. Interactive Financial Services Ltd is the IPO’s book running lead manager.

Business Model

The company's products span across the family of pharmaceutical intermediates, active pharmaceutical ingredients, nutraceutical APIs and ingredients for personal care and veterinary API. In addition to the manufacturing of pharma intermediate and APIs, the company has recently started undertaking custom manufacturing services for complex or novel chemical compounds, tailoring the manufacturing process to meet specific customer requirements.

Company Growth Trajectory

The revenue from operations of Anlon Healthcare Ltd grew from ₹113.1200 crores in FY 23 to ₹120.4551 crores in FY 25, while EBITDA margin grew from 18.51% in FY 23 to 26.88% in FY 25. Net profit margin grew from 5.16% in FY 23 to 17.06% in FY 25. Strong product portfolio and scalable business have helped in the company’s growth over the years.

Market Position

In addition to its domestic market sales in India, the company has expanded its scale of operations and global footprint with customers in over 15 countries including Italy, Germany, South Korea, China, Argentina, Chile, Columbia, Mexico, Egypt, Turkey, Japan, Brazil, United Kingdom, United Arab Emirates etc. among others.

How to Check Allotment Status of Anlon Healthcare IPO?

You can check the allotment status of Anlon Healthcare Ltd either through the BSE website or through the registrar’s website. To check the status through BSE website:

• Visit the BSE website
• Click on “Investor Services” and choose “Application Status Check”
• Choose the issue type — Equity or Debt
• Select the Issue Name from the drop-down
• Enter your application number or PAN number
• Check the box that says “I’m not a Robot” and click on “Search” to know the allotment status

To check the status from the registrar’s website:

• Visit the website of KFin Technologies Ltd
• Choose IPO allotment status from “Products’ dropdown
• Click on any of the links
• Select the IPO
• Input either your application number, PAN number or Demat number
• Enter captcha and click on Submit

How to Apply for Anlon Healthcare IPO?

To apply for this IPO:

• Step 1: Log in to your Kotak Securities Demat account: Log in to your Demat account to access IPO investments. Next, select the current IPO section.
• Step 2: Specify IPO details: Enter the number of lots and the price you wish to apply for.
• Step 3: Enter UPI ID After entering your UPI ID, click submit. This will place your bid with the exchange.
• Step 4: Mandate Notification: Your UPI app will receive a mandate notification to block funds.
• Step 5: Approve Request Your funds will be blocked once you approve the mandate request on your UPI.